FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer. PMID 36529613 · Clin Colorectal Cancer · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations. PMID 36528522 · Clin Lung Cancer · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): a prospective single-center registry study. PMID 36513815 · J Cancer Res Clin Oncol · 2023-Mar The record is a prospective registry study, not a randomized controlled trial. While it meets criteria for oncology, human, drug intervention, and time-to-event endpoint, it fails the randomized and Phase III/IIIb or Phase II/III requirements. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate. PMID 36511888 · Pediatr Dermatol · 2023-Mar This is a secondary analysis of a Phase II/III trial for a drug intervention. While it involves a neoplasm (infantile hemangioma) and reports a result, it is not a primary randomized trial report and its primary endpoint is a categorical success rate at a fixed time point, not a time-to-event endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Corrigendum to "Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial" [Eur Urol (2022)]. PMID 36503643 · Eur Urol · 2023-Mar The record is a published erratum for a screening trial. It does not meet the core criteria: it is not an original result report, it does not contain a drug intervention, and no time-to-event efficacy endpoint is established from the provided metadata. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. PMID 36494006 · Ann Oncol · 2023-Mar The abstract explicitly details results from two large randomized trials (KEYNOTE-045 and KEYNOTE-052) evaluating pembrolizumab in metastatic urothelial carcinoma. KEYNOTE-045 is a randomized, Phase III trial with primary time-to-event endpoints (OS, PFS), meeting all eligibility criteria. KEYNOTE-052 is a single-arm trial, but the overall report's inclusion is justified by the definitive Phase III data from KEYNOTE-045. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| A 5-year survival status prognosis of nonmetastatic cervical cancer patients through machine learning algorithms. PMID 36479910 · Cancer Med · 2023-Mar The study is an oncology, human, randomized (as per publication type) trial with original primary results. However, it is ineligible because it lacks a drug-containing intervention (it is a predictive modeling study using existing data) and does not have a time-to-event efficacy endpoint (it uses binary classification, not survival analysis with KM/HR). The phase is not definitively established as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prognostic nomogram based on the lymph node metastasis indicators for patients with bladder cancer: A SEER population-based study and external validation. PMID 36479835 · Cancer Med · 2023-Mar The record is a prognostic nomogram study using SEER registry data and TCGA genomics, not a randomized controlled trial of a drug intervention. Despite the publication type 'Randomized Controlled Trial' in metadata, the study design is clearly observational (retrospective cohort from databases) with no drug intervention, no randomization to treatment arms, and no Phase III trial context. The endpoints are overall survival and cause-specific survival used for prognostic modeling, not for evaluating a drug's efficacy. Therefore, it does not meet the required criteria for a drug-containing randomized oncology trial with a primary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| An online randomised controlled trial of prognosticating imminent death in advanced cancer patients: Clinicians give greater weight to advice from a prognostic algorithm than from another clinician with a different profession. PMID 36444695 · Cancer Med · 2023-Mar The study is a randomized controlled trial in advanced cancer patients (oncology, human, randomized, original result) but is not a drug trial (no drug intervention) and does not report a time-to-event efficacy endpoint (primary outcome is Weight of Advice, a behavioral measure). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Intraoperative frozen pathology exam of Common iliac lymph nodes and Para-Aortic lymphadenectomy on the prognosis and quality of life for patients with IB2-IIA2 Cervical Cancer: trial protocol for a randomized controlled trial (C-PACC trial). PMID 36424705 · J Gynecol Oncol · 2023-Mar 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A randomised evaluation of low-dose Ara-C plus pegylated recombinant arginase BCT-100 versus low dose Ara-C in older unfit patients with acute myeloid leukaemia: Results from the LI-1 trial. PMID 36413792 · Br J Haematol · 2023-Mar The study is a randomized, drug-intervention trial in human oncology (AML) with a time-to-event endpoint (survival). However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the title, abstract, or metadata; it is described only as a 'randomised study'. Therefore, the 'phase3_or_definitive' criterion cannot be established as true from the provided information, leading to ineligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A phase III randomized trial evaluating the quality of life impact of a tailored versus systematic use of defunctioning ileostomy following total mesorectal excision for rectal cancer-GRECCAR 17 trial protocol. PMID 36413078 · Colorectal Dis · 2023-Mar 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Internet-administered, low-intensity cognitive behavioral therapy for parents of children treated for cancer: A feasibility trial (ENGAGE). PMID 36404407 · Cancer Med · 2023-Mar The study is a single-arm feasibility trial of a psychological intervention (LICBT) for parents of children with cancer. It does not meet the required criteria of being a randomized Phase III/IIIb or Phase II/III trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Novel prognostic nomograms in cervical cancer based on analysis of 1075 patients. PMID 36394197 · Cancer Med · 2023-Mar The study is a retrospective, single-center analysis of prognostic factors for cervical cancer, constructing nomograms for DFS and OS. While it is an oncology study with human patients, randomized data splitting, and time-to-event endpoints, it is not a Phase III or definitive randomized trial evaluating a drug-containing intervention. The publication type includes 'Randomized Controlled Trial', but the study design is retrospective and does not represent a drug intervention trial, thus failing the drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. PMID 36370871 · Am J Obstet Gynecol · 2023-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| 5 year oncological outcomes of the HIGHLOW randomized clinical trial. PMID 36335077 · Eur J Surg Oncol · 2023-Mar 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Prophylactic EUS-guided gallbladder drainage prevents acute cholecystitis in patients with malignant biliary obstruction and cystic duct orifice involvement: a randomized trial (with video). PMID 36328209 · Gastrointest Endosc · 2023-Mar 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Impact of margin ablation after EMR of large nonpedunculated colonic polyps in routine clinical practice. PMID 36328207 · Gastrointest Endosc · 2023-Mar The study is a relevant oncology-related RCT but is excluded because it does not involve a drug intervention and does not have a primary time-to-event efficacy endpoint as defined by the cohort criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A novel nomogram and risk classification system for predicting overall survival in head and neck squamous cell cancer with distant metastasis at initial diagnosis. PMID 36316576 · Eur Arch Otorhinolaryngol · 2023-Mar The study is a retrospective, non-interventional cohort analysis using SEER registry data to develop a prognostic nomogram. While it involves oncology, humans, survival analysis, and reports random assignment to training/validation cohorts, it is not a randomized controlled trial (RCT) testing a specific drug intervention against a control. The publication type 'Randomized Controlled Trial' in the metadata appears to be a misclassification. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Underwater versus conventional EMR for nonpedunculated colorectal lesions: a randomized clinical trial. PMID 36309072 · Gastrointest Endosc · 2023-Mar The study is a randomized controlled trial in oncology (colorectal lesions) and reports original results, but it does not involve a drug-containing intervention (compares endoscopic techniques) and does not have a primary or key secondary time-to-event efficacy endpoint (recurrence rate is a binary outcome at a fixed time point, not time-to-event). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clustering on longitudinal quality-of-life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial. PMID 36281472 · Cancer Med · 2023-Mar This is an eligible randomized oncology trial with drug intervention and time-to-event endpoint. However, it is excluded because it is not the primary efficacy result report of the trial. It is a secondary analysis using QoL data for prognostic clustering, which falls under the exclusion criteria for 'post-hoc subgroup, biomarker-only, quality-of-life... analyses'. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Transbronchial needle aspiration combined with cryobiopsy in the diagnosis of mediastinal diseases: a multicentre, open-label, randomised trial. PMID 36279880 · Lancet Respir Med · 2023-Mar The trial is an open-label randomised study evaluating a diagnostic procedure (cryobiopsy combined with EBUS-TBNA) for mediastinal diseases. It does not involve a drug-containing intervention (neither arm includes a drug therapy). The primary outcome is diagnostic yield (a proportion), not a time-to-event efficacy endpoint (e.g., OS, PFS). While it involves human oncology (lung cancer mentioned), it fails two key eligibility criteria: drug intervention and time-to-event endpoint. The phase is not explicitly stated as Phase III or II/III, further excluding it. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Survival prediction for patients with malignant biliary obstruction caused by pancreatic cancer undergoing biliary drainage: the COMBO-PaS model. PMID 36261643 · Surg Endosc · 2023-Mar The study is a retrospective, randomized (for model development/validation) prognostic model study for survival in pancreatic cancer patients undergoing biliary drainage. It is oncology and human, but it lacks a drug-containing intervention and does not report on a Phase III/IIIb or Phase II/III randomized trial of a therapeutic intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Trial sequential meta-analysis of laparoscopic versus open pancreaticoduodenectomy: is it the time to stop the randomization? PMID 36253625 · Surg Endosc · 2023-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of a High-Fat Meal on Single-Dose Rencofilstat (CRV431) Oral Bioavailability in Healthy Human Subjects. PMID 36251165 · Clin Pharmacol Drug Dev · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| 18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus-Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002. PMID 36215572 · J Nucl Med · 2023-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Nomograms Combining Clinical and Imaging Parameters to Predict Recurrence and Disease-free Survival After Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer. PMID 36050264 · Acad Radiol · 2023-Mar The study is a retrospective analysis developing and validating predictive nomograms for recurrence and disease-free survival in cervical cancer patients treated with concurrent chemoradiotherapy. While it is oncological, human, includes DFS, and is reported as a randomized controlled trial, it fails two critical eligibility criteria: 1) It does not establish a Phase III/IIIb or Phase II/III trial phase; the randomization is for model development, not treatment comparison. 2) The intervention (concurrent chemoradiotherapy) is not the subject of a drug-containing experimental arm evaluation; the study's purpose is predictive modeling, not efficacy assessment of a drug regimen. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trial. PMID 36045304 · Cancer Immunol Immunother · 2023-Mar The trial is explicitly described as a phase 2b study. The required criterion of being a Phase III/IIIb or Phase II/III randomized trial is not met. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Synbiotics in Reducing the Systemic Inflammatory Response and Septic Complications in Moderately Severe and Severe Acute Pancreatitis: A Prospective Parallel-Arm Double-Blind Randomized Trial. PMID 35857241 · Dig Dis Sci · 2023-Mar The study is a randomized trial in humans with original results, but it is not an oncology study (acute pancreatitis, not malignant neoplasm). The intervention is synbiotics (probiotics/prebiotics), which is not a standard drug-containing intervention. The primary endpoint is septic complications, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Direct Percutaneous Endoscopic Gastrostomy Versus Radiological Gastrostomy in Patients Unable to Undergo Transoral Endoscopic Pull Gastrostomy. PMID 35708794 · Dig Dis Sci · 2023-Mar Excluded because it is a non-randomized procedural comparison without drug intervention and lacks the required time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Is ultra-hypo-fractionated radiotherapy more cost-effective relative to conventional fractionation in treatment of prostate cancer? A cost-utility analysis alongside a randomized HYPO-RT-PC trial. PMID 35587847 · Eur J Health Econ · 2023-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Can whole-body MRI replace CT in management of metastatic testicular cancer? A prospective, non-inferiority study. PMID 35389110 · J Cancer Res Clin Oncol · 2023-Mar This is a prospective, non-randomized study comparing imaging modalities (MRI vs CT) for testicular cancer. It lacks randomization, does not evaluate a drug intervention, and its primary endpoint is diagnostic accuracy (sensitivity), not a time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prophylactic A-Blockers for Radiotherapy-Induced Lower Urinary Tract Symptoms in Men with Prostate Cancer: A Phase III Randomized Trial. PMID 37444553 · Cancers (Basel) · 2023-Jun-30 The study is a Phase III randomized trial with a drug intervention (α-blocker) in human prostate cancer (oncology). However, the primary endpoint is change in IPSS (a patient-reported symptom score), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or analysis using Kaplan-Meier/HR). The report is the primary result of a randomized trial, but it fails the mandatory time-to-event criterion. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort. PMID 37444551 · Cancers (Basel) · 2023-Jun-30 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Comparison of the cytokine adsorption ability in continuous renal replacement therapy using polyethyleneimine-coated polyacrylonitrile (AN69ST) or polymethylmethacrylate (PMMA) hemofilters: a pilot single-center open-label randomized control trial. PMID 37391846 · Eur J Med Res · 2023-Jun-30 The study is a randomized controlled trial in sepsis patients comparing two types of CRRT hemofilters (AN69ST vs. PMMA). It is not an oncology study, does not involve a drug intervention, does not report a time-to-event efficacy endpoint with Kaplan-Meier or HR, and the trial phase is not specified as Phase II/III or III. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Cervical Screening Reminders for Aboriginal and Torres Strait Islander Women in Primary Care-Randomised Controlled Trial of Letter vs. Phone/SMS Reminders. PMID 37444104 · Int J Environ Res Public Health · 2023-Jun-29 The study is a randomized controlled trial in an oncology context (cervical cancer screening) but lacks the required drug intervention and time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, KM, HR). The primary outcome is attendance for screening, not a survival or progression endpoint. Phase is not specified, so phase3_or_definitive is null. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tumor burden score-AFP-albumin-bilirubin grade score predicts the survival of patients with hepatocellular carcinoma after liver resection. PMID 37382724 · Langenbecks Arch Surg · 2023-Jun-29 The record describes a prognostic model development study for overall survival after liver resection. While it is an oncology study with a time-to-event endpoint and uses a randomized split for analysis, it is not a randomized clinical trial (RCT) of a drug intervention. The publication type 'Randomized Controlled Trial' appears to be a misclassification, as the study itself is retrospective and not a comparative trial of a drug. The study does not meet the key criteria of being a Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. PMID 37379135 · N Engl J Med · 2023-Jun-29 The study is a Phase III randomized controlled trial of mirikizumab for ulcerative colitis, which is not a malignant neoplasm (oncology). The primary endpoints are clinical remission and response, not time-to-event efficacy endpoints as required. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Preserving or peeling the inferior mesenteric arterial sheath during laparoscopic rectal cancer surgery: a prospective study of surgical outcomes. PMID 37370110 · BMC Surg · 2023-Jun-27 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Developing the evidence and associated service models to support older adults living with frailty to manage their pain and to reduce its impact on their lives: protocol for a mixed-method, co-design study (The POPPY Study). PMID 37369419 · BMJ Open · 2023-Jun-26 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Photoaging and theory-based intervention to improve sun protection behaviors in students in Zahedan: study protocol for a randomized controlled trial. PMID 37365669 · Trials · 2023-Jun-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial. PMID 37355621 · J Transl Med · 2023-Jun-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Bilaterally parallel elliptic flap versus Karydakis flap in primary pilonidal sinus disease: a randomized controlled trial. PMID 37351640 · Int J Colorectal Dis · 2023-Jun-23 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Influence of Intravenous Lidocaine Infusion on Postoperative Outcome and Neutrophil-to-Lymphocyte Ratio in Colorectal Cancer Patients. A Pilot Study. PMID 37345602 · J Gastrointestin Liver Dis · 2023-Jun-22 This is a randomized, double-blind, placebo-controlled trial assessing intravenous lidocaine infusion in colorectal cancer patients. While it is an oncology study with human participants, randomized design, drug intervention, and reports time-to-event outcomes (1-year recurrence and survival), it is not eligible because: 1) The phase of the trial is not explicitly stated; it is described as a 'pilot study', which does not establish Phase III/IIIb or Phase II/III definitive status. 2) The primary focus is on postoperative recovery (pain, mobilization, hospital stay) and a biomarker (neutrophil-to-lymphocyte ratio), not a predefined primary or key secondary oncology efficacy endpoint (like OS, PFS, DFS). The 1-year recurrence and survival are reported as secondary outcomes, but the trial is not designed as a definitive oncology efficacy trial. Therefore, it does not meet the strict eligibility criteria for a definitive randomized trial with a primary/key secondary time-to-event oncology efficacy endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. PMID 37341189 · Cochrane Database Syst Rev · 2023-Jun-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Vitamin D Supplementation and Adherence to World Cancer Research Fund (WCRF) Diet Recommendations for Colorectal Cancer Prevention: A Nested Prospective Cohort Study of a Phase II Randomized Trial. PMID 37371861 · Biomedicines · 2023-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Current evidence for moderate and ultra-hypofractionated radiation therapy in prostate cancer: a summary of the results from phase 3 randomised trials. PMID 37338209 · Scand J Urol · 2023-Jun-20 The record is a review of multiple phase III randomized trials in prostate cancer, but it does not involve a drug-containing intervention (only radiation therapy comparisons) and does not report a primary/key secondary time-to-event efficacy endpoint. The endpoints are tumour control (binary) and toxicity rates, not time-to-event outcomes like OS or PFS. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II Randomized Trial of Lenalidomide in Children With Pilocytic Astrocytomas and Optic Pathway Gliomas: A Report From the Children's Oncology Group. PMID 37126770 · J Clin Oncol · 2023-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer. PMID 37023374 · J Clin Oncol · 2023-Jun-20 The record describes a randomized trial with a drug intervention (lidocaine) and a primary time-to-event endpoint (DFS) in breast cancer, meeting several core criteria. However, the trial phase is not explicitly stated as Phase III or equivalent in the provided text, which is required for eligibility under the strict criteria. Therefore, is_eligible is set to false due to the lack of definitive phase evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| PYloroplasty versus No Intervention in GAstric REmnant REconstruction after Oesophagectomy: study protocol for the PYNI-GAREREO phase III randomized controlled trial. PMID 37337238 · Trials · 2023-Jun-19 方案论文未报告临床试验结果。 |
H
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |